DB:19T

Stock Analysis Report

Executive Summary

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has Idorsia's share price performed over time and what events caused price changes?


Latest Share Price and Events

Information is not available.


Market Performance


7 Day Return

0%

19T

-1.4%

DE Biotechs

0.1%

DE Market


1 Year Return

-9.7%

19T

-6.9%

DE Biotechs

8.8%

DE Market

Return vs Industry: 19T underperformed the German Biotechs industry which returned -6.9% over the past year.

Return vs Market: 19T underperformed the German Market which returned 8.8% over the past year.


Shareholder returns

19TIndustryMarket
7 Day0%-1.4%0.1%
30 Day0%-2.4%5.9%
90 Day6.3%-7.9%15.0%
1 Year-9.7%-9.7%-6.6%-6.9%12.2%8.8%
3 Yearn/a54.7%52.6%25.5%14.5%
5 Yearn/a-1.5%-4.6%40.1%21.0%

Price Volatility Vs. Market

How volatile is Idorsia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Idorsia undervalued compared to its fair value and its price relative to the market?

7.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 19T's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 19T's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 19T is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 19T is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 19T's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 19T is overvalued based on its PB Ratio (7.3x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Idorsia forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

14.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 19T is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 19T is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 19T is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 19T's revenue (42.6% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: 19T's revenue (42.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 19T's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Idorsia performed over the past 5 years?

-178.6%

Last years earnings growth


Earnings and Revenue History

Information is not available.

Information is not available.


Past Earnings Growth Analysis

Earnings Trend: 19T is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare 19T's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 19T is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 19T has a negative Return on Equity (-105.74%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Idorsia's financial position?


Financial Position Analysis

Short Term Liabilities: 19T's short term assets (CHF710.4M) exceeds its short term liabilities (CHF120.1M)

Long Term Liabilities: 19T's short term assets (710.4M) exceeds its long term liabilities (705.3M)


Debt to Equity History and Analysis

Debt Level: 19T's debt to equity ratio (132%) is considered high

Reducing Debt: Insufficient data to determine if 19T's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 19T has a low level of unsold assets or inventory.

Debt Coverage by Assets: 19T's debt is covered by short term assets (assets are 1.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 19T has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 19T has sufficient cash runway for 2.106107 years if free cash flow continues to reduce at historical rates of -46.2% each year.


Next Steps

Dividend

What is Idorsia's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 19T's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 19T's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 19T's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 19T's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 19T's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Idorsia's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average board tenure


CEO

Jean-Paul Clozel (64yo)

0yrs

Tenure

0

Mr. Jean-Paul Clozel, M.D., co- founded Actelion Ltd (alternate name Actelion AG ) in 1997 and has been its Chief Executive Officer since 1999. Mr. Clozel serves as the Chief Executive Officer of Idorsia L ...


Board Age and Tenure

1.4yrs

Average Tenure

64yo

Average Age

Experienced Board: 19T's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Information is not available.


Management Team

  • Jean-Paul Clozel (64yo)

    CEO & Director

    • Tenure: 0yrs
  • Martine Clozel (64yo)

    Executive VP & Chief Scientific Officer

    • Tenure: 0yrs
  • Guy Braunstein (63yo)

    Executive VP & Head of Global Clinical Development

    • Tenure: 0yrs
  • Simon Jose

    Chief Commercial Officer

    • Tenure: 0.8yrs
  • André Muller (56yo)

    Executive VP & CFO

    • Tenure: 0yrs
  • Andrew Weiss (51yo)

    Senior VP and Head of Investor Relations & Corporate Communications

    • Tenure: 0yrs

Board Members

  • JP Garnier (72yo)

    Chairman of the Board

    • Tenure: 8yrs
  • Jean-Paul Clozel (64yo)

    CEO & Director

    • Tenure: 0yrs
  • David Stout (64yo)

    Director

    • Tenure: 0yrs
  • Bob Bertolini (58yo)

    Director

    • Tenure: 0yrs
  • John Greisch (64yo)

    Director

    • Tenure: 0yrs
  • Mathieu Simon (63yo)

    Director

    • Tenure: 0.3yrs
  • Viviane Monges (56yo)

    Director

    • Tenure: 1.4yrs

Company Information

Idorsia Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Idorsia Ltd
  • Ticker: 19T
  • Exchange: DB
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF3.247b
  • Listing Market Cap: CHF2.994b
  • Shares outstanding: 131.23m
  • Website: https://www.idorsia.com

Number of Employees


Location

  • Idorsia Ltd
  • Hegenheimermattweg 91
  • Allschwil
  • Basel-Landschaft
  • 4123
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IDIASWX (SIX Swiss Exchange)YesCommon SharesCHCHFJun 2017
0RQELSE (London Stock Exchange)YesCommon SharesGBCHFJun 2017
19TDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2017
IDRS.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJun 2017

Biography

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. The company has collaboration agreements with Johnson & Johnson to jointly develop and comme ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/25 22:37
End of Day Share Price2019/06/28 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.